


Melanoom en de rol van de dermatoloog

Dr. Annemiek Leeman
Dermatoloog UZ Leuven
25 januari 2025

- Het opsporen van recidieven en uitzaaiingen
- Het opsporen van nieuwe melanomen
- Het behandelen van huidafwijkingen gerelateerd aan immuuntherapie



- Total body Imaging met AI en digitale dermatoscopie
- Het opsporen van patiënten met een hoog risico op het krijgen van melanomen
- Gepersonaliseerde follow-up



SAMEN
GRENZEN
VERLEGGEN

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

Jedd D Wolchok, Bart Neyns, Gerald Linette, Sylvie Negrier, Jose Lutzky, Luc Thomas, William Waterfield, Dirk Schadendorf, Michael Smylie, Troy Guthrie Jr, Jean-Jacques Grob, Jason Chesney, Kevin Chin, Kun Chen, Axel Hoos, Steven J O'Day, Celeste Lebbé













Figure 2: Kaplan-Meier estimate for overall survival, by treatment arm

Response to anti-PD-1 [Pembrolizumab EAP]

72y F, stage IV-M1d
BRAF V600E, failed Vemurafenib, WBRT
Baseline CRP 6 mg/dl, LDH 836 mg/dl



2 administrations
of pembrolizumab



17NOV2014




9DEC2014

26DEC2014

30MAR2015

CASE ILLUSTRATION

- Patient 2: Woman in her 60s with stage IV-M1a melanoma (right lower leg), BRAF^{V600E/D}
- **Refractory to NIVO and local radiotherapy**
- Grade 3-4 irAE gastritis/enteritis on IPI/NIVO - grade 3-4 irAE recurrent pancreatitis and hepatitis on DAB/TRAME - grade 2 eye toxicity (MEKAR) on ENCO/BINI
- **Start trial April 2023**




Medische beeldvorming doorheen de jaren

Studiedag Melanoompunt 25-1-2025




Cindy Mai
Dienst Radiologie
Universitair Ziekenhuis Antwerpen

Rol van beeldvorming in het proces





Evolutie van oncologische beeldvorming



AI anno 2024-2025

Op dit moment
eenvoudige
opdrachten



In de toekomst automatisch
gegenereerd verslag bij elk
onderzoek met diagnose,
ziekte-evolutie, risico-
inschatting/kans op herval

Referenties

- Garbe, Claus et al. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024. European Journal of Cancer, Volume 215, 115152
- Avanzo M, Stancanello J, Pirrone G, Drigo A, Retico A. The Evolution of Artificial Intelligence in Medical Imaging: From Computer Science to Machine and Deep Learning. Cancers (Basel). 2024 Nov 1;16(21):3702. doi: 10.3390/cancers16213702. PMID: 39518140; PMCID: PMC11545079.
- Natasha Davendralingam, Neil J Sebire, Owen J Arthurs, Susan C Shelmerdine, Artificial intelligence in paediatric radiology: Future opportunities. British Journal of Radiology. Volume 94. Issue 1117. 1 January 2021. 20200975


IMPACT OP CONSULTATIES

DR. NINA DE MOOR
MEDISCH ONCOLOOG


JESSA
ZIEKENHUIS

Incidentie van melanomen

In stijgende lijn in België



Multidisciplinair consult



En de toekomst?

Medische innovatie en de evolutie van kankerbehandelingen

Dr. Paul Lacante

Medisch Directeur

Bristol Myers Squibb Benelux


Evolutie van kankerbehandeling



Chirurgie (1846)




Chemotherapie (1946)




Immuno-oncologie (2011)



Radiotherapie (1901)




Doelgerichte therapie (1997)



1. DeVita VT Jr, et al. Cancer Res. 2008;68:8643-8653; 2. American Cancer Society. <http://www.cancer.org/cancer/cancerbasics/thehistoryofcancer/>; 3. Hodi FS, et al. N Engl J Med. 2010;363:711-723; 4. Sznol M, et al. Presented at ASCO 2013: oral presentation; 5. Kantoff PW, et al. N Engl J Med. 2010;363:411-422; 6. Finn OJ. Ann Oncol. 2012;23(suppl 8):viii6-viii9.

Melanoomverloop en immuno-oncologie




1. Velho TR. *Drugs Context*. 2012;2012:212242.
2. Dummer R, et al. *Lancet Oncol*. 2018;19(10):1315-1327.
3. Wolchok J, et al. *N Engl J Med*. 2024;391:1345-1356.
4. <https://www.fda.gov/Drugs/InformationOnDrugs/default.htm>


BRAF, serine-threonine protein kinase B-raf; Chemo, chemotherapy; CTLA-4, cytotoxic T lymphocyte antigen-4; IL2, interleukin 2; IPI, ipilimumab; MEK, mitogen-activated protein kinase; mo, month; mono, monotherapy; mOS, median overall survival; NIVO, nivolumab; OS, overall survival; PD-1, programmed cell death protein 1.

Overlevingskans (OS) aanzienlijk verhoogd dankzij immuno-oncologie (IO)

Gemiddelde overleving voor de beschikbaarheid van IO




Gemiddelde overleving met duale IO




1. Korn E, et al. *J Clin Oncol*. 2008;26(4):527-534. 2. Wolchok J, et al. *N Engl J Med*. 2024;391:1345-1356.

Breedte en diepte van de pijplijn voor solide tumoren



[BMS in the pipeline. Accessed January 20, 2025](#)

IMMUNO-ONCOLOGY
AN INNOVATION WHOSE SUCCESS
CONTINUES TO SHINE



BRISTOL MYERS SQUIBB
PIONEER IN **DUAL** IMMUNO-ONCOLOGY

